By Teddy Cambosa
The Philippine government has announced that it will be receiving 3 million doses of the Sputnik V vaccine after issuing an emergency use authorization (EUA) grant from the nation’s Food and Drug Administration (FDA).
The vaccine, developed by Russian research institute Gamaleya Institute, is requested to be rolled out nationwide this coming April or May this year, according to National Task Force Against Covid-19 chief implementer Carlito Galvez Jr.
“More or less, 20 to 30 countries are using the Gamaleya Sputnik V. And we are requesting to procure at least two million doses this coming April.”
Talks are also on the way to encourage local government units to procure the said vaccine.
The EUA was granted after the FDA announced that interim data from the ongoing phase three trials of Gamaleya National Center of Epidemiology and Microbiology showed an overall efficacy of 91.6 percent in preventing COVID-19.
Sputnik V, a two-dose vaccine administered in 0.5 ml intramuscular injections 21 days apart, is the latest vaccine to receive an EUA in the Philippines after Pfizer-BioNTech, AstraZeneca, and Sinovac.
Teddy Cambosa is a graduating BS Biology student and a former campus journalist at Batangas State University. He is also currently writing for MARKETECH APAC, a small APAC-focused marketing news site.
- New antibiotic compound effective against multi-drug resistant gonorrhea in mice
- European officials: COVID-19 Vaccine AstraZeneca not associated with an increase in the overall risk of blood clots
- Tularemia reported in Rhode Island rabbit
- WHO: Benefits of the AstraZeneca vaccine outweigh its risks
- Researchers find aspirin may have lung-protective effects and reduce the need for mechanical ventilation, ICU admission and deaths in hospitalized COVID-19 patients
- Paraguay: Dengue cases continue to increase
- Sweden: Yersinia enterocolitica outbreak over, Iceberg lettuce is the suspected source
